Dose selection in phase I clinical trials in oncology

• In: Symposium E3: Medicines for the real life population: the science of extrapolation on Tuesday, 23 May 2017, 15:35-16:05
• At: Stockholm (Sweden) (2017)
• Type: Presentation
• By: SCHELLENS, Jan (Netherlands Cancer Institute & University Utrecht, Clinical Pharmacology, Amsterdam, Netherlands)
• Co-author(s): Jan HM Schellens: Clinical Pharmacology, Netherlands Cancer Institute & University Utrecht, Amsterdam, Netherlands
  
• Abstract:

  Phase I studies in oncology are often carried out in patients with advanced cancer with the aim the select a safe dose and schedule for further testing in later phase II and III studies. Selection of the wrong dose and schedule can kill a good drug, which is a waist for patients and the pharmaceutical industry. Cabozantonib is a RET inhibitor

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login